{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:11:31Z","timestamp":1740107491771,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21fk0210084"],"award-info":[{"award-number":["JP21fk0210084"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00535-021-01826-8","type":"journal-article","created":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T08:09:02Z","timestamp":1633075742000},"page":"1008-1021","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs"],"prefix":"10.1007","volume":"56","author":[{"given":"Daiki","family":"Yamashige","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0302-2275","authenticated-orcid":false,"given":"Tetsuya","family":"Hosaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumitaka","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunichiro","family":"Fujiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Sezaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Akuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Saitoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuji","family":"Arase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Kumada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,1]]},"reference":[{"issue":"9959","key":"1826_CR1","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","volume":"384","author":"C Tr\u00e9po","year":"2014","unstructured":"Tr\u00e9po C, Chan HLY, Lok A. Hepatitis B virus infection. Lancet. 2014;384(9959):2053\u201363.","journal-title":"Lancet"},{"key":"1826_CR2","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa033364","volume":"351","author":"YF Liaw","year":"2004","unstructured":"Liaw YF, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521\u201331.","journal-title":"N Engl J Med"},{"key":"1826_CR3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/hep.26180","volume":"58","author":"T Hosaka","year":"2013","unstructured":"Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58:98\u2013107.","journal-title":"Hepatology"},{"key":"1826_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1053\/j.gastro.2014.03.048","volume":"147","author":"CY Wu","year":"2014","unstructured":"Wu CY, Lin JT, Ho HJ, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B\u2014a nationwide cohort study. Gastroenterology. 2014;147:143\u2013151.e5.","journal-title":"Gastroenterology"},{"key":"1826_CR5","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","volume":"137","author":"F Zoulim","year":"2009","unstructured":"Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009;137:1593\u2013608.e1.","journal-title":"Gastroenterology"},{"key":"1826_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/hep.20760","volume":"42","author":"GV Papatheodoridis","year":"2005","unstructured":"Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology. 2005;42:121\u20139.","journal-title":"Hepatology"},{"key":"1826_CR7","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1128\/AAC.00833-06","volume":"51","author":"DJ Tenney","year":"2007","unstructured":"Tenney DJ, Rose RE, Baldick CJ, et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother. 2007;51:902\u201311.","journal-title":"Antimicrob Agents Chemother"},{"key":"1826_CR8","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/hep.22211","volume":"47","author":"CJ Baldick","year":"2008","unstructured":"Baldick CJ, Tenney DJ, Mazzucco CE, et al. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology. 2008;47:1473\u201382.","journal-title":"Hepatology"},{"key":"1826_CR9","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1136\/gutjnl-2014-308353","volume":"65","author":"YS Lim","year":"2016","unstructured":"Lim YS, Byun KS, Yoo BC, et al. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. Gut. 2016;65:852\u201360.","journal-title":"Gut"},{"key":"1826_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/jvh.12613","volume":"24","author":"Y Liu","year":"2017","unstructured":"Liu Y, Corsa AC, Buti M, et al. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg\u2212 patients with chronic hepatitis B after 8 years of treatment. J Viral Hepat. 2017;24:68\u201374.","journal-title":"J Viral Hepat"},{"key":"1826_CR11","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1053\/j.gastro.2013.12.028","volume":"146","author":"S Fung","year":"2014","unstructured":"Fung S, Kwan P, Fabri M, et al. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2014;146:980\u20138.","journal-title":"Gastroenterology"},{"key":"1826_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1136\/gut.2010.223206","volume":"60","author":"SJ Patterson","year":"2011","unstructured":"Patterson SJ, George J, Strasser SI, et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut. 2011;60:247\u201354.","journal-title":"Gut"},{"key":"1826_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3350\/cmh.2016.0060","volume":"23","author":"GE Chung","year":"2017","unstructured":"Chung GE, Cho EJ, Lee JH, et al. Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-na\u00efve patients. Clin Mol Hepatol. 2017;23:66\u201373.","journal-title":"Clin Mol Hepatol"},{"key":"1826_CR14","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.jhep.2019.02.006","volume":"70","author":"ES Park","year":"2019","unstructured":"Park ES, Lee AR, Kim DH, et al. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. J Hepatol. 2019;70:1093\u2013102.","journal-title":"J Hepatol"},{"key":"1826_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/jvh.13397","volume":"28","author":"Y Liu","year":"2021","unstructured":"Liu Y, Chang S, Martin R, et al. Characterization of hepatitis B virus polymerase mutations A194T and CYEI and tenofovir disoproxil fumarate or tenofovir alafenamide resistance. J Viral Hepat. 2021;28:30\u20139.","journal-title":"J Viral Hepat"},{"key":"1826_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","volume":"1","author":"HLY Chan","year":"2016","unstructured":"Chan HLY, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:185\u201395.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1826_CR17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","volume":"1","author":"M Buti","year":"2016","unstructured":"Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196\u2013206.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1826_CR18","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/jmv.20658","volume":"78","author":"F Suzuki","year":"2006","unstructured":"Suzuki F, Kumada H, Nakamura H. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy. J Med Virol. 2006;78:1025\u201334.","journal-title":"J Med Virol"},{"key":"1826_CR19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/hepr.13618","volume":"51","author":"F Suzuki","year":"2021","unstructured":"Suzuki F, Sezaki H, Hosaka T, et al. Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir. Hepatol Res. 2021;51:503\u20138.","journal-title":"Hepatol Res"},{"key":"1826_CR20","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","volume":"5","author":"P Lampertico","year":"2020","unstructured":"Lampertico P, Buti M, Fung S, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol Hepatol. 2020;5:441\u201353.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1826_CR21","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","volume":"68","author":"K Agarwal","year":"2018","unstructured":"Agarwal K, Brunetto M, Seto WK, et al. 96 Weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68:672\u201381.","journal-title":"J Hepatol"},{"key":"1826_CR22","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1111\/liv.14482","volume":"40","author":"E Ogawa","year":"2020","unstructured":"Ogawa E, Nomura H, Nakamuta M, et al. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. Liver Int. 2020;40:1578\u201389.","journal-title":"Liver Int"},{"key":"1826_CR23","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/135965350701200309","volume":"12","author":"X Qi","year":"2007","unstructured":"Qi X, Xiong S, Yang H, et al. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther. 2007;12:355\u201362.","journal-title":"Antivir Ther"},{"key":"1826_CR24","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1136\/gutjnl-2014-308435","volume":"65","author":"YS Lim","year":"2016","unstructured":"Lim YS, Yoo BC, Byun KS, et al. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. Gut. 2016;65:1042\u201351.","journal-title":"Gut"},{"key":"1826_CR25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.23246","volume":"51","author":"F van B\u00f6mmel","year":"2010","unstructured":"van B\u00f6mmel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside\/nucleotide analogues. Hepatology. 2010;51:73\u201380.","journal-title":"Hepatology"},{"key":"1826_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/jvh.12623","volume":"24","author":"S Lee","year":"2017","unstructured":"Lee S, Ahn SH, Jung KS, et al. Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance. J Viral Hepat. 2017;24:141\u20137.","journal-title":"J Viral Hepat"},{"key":"1826_CR27","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S1473-3099(11)70314-0","volume":"12","author":"R Gish","year":"2012","unstructured":"Gish R, Jia JD, Locarnini S, et al. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis. 2012;12:341\u201353.","journal-title":"Lancet Infect Dis"},{"key":"1826_CR28","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/hep.29187","volume":"66","author":"YS Lim","year":"2017","unstructured":"Lim YS, Lee YS, Gwak GY, et al. Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial. Hepatology. 2017;66:772\u201383.","journal-title":"Hepatology"},{"key":"1826_CR29","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560\u201399.","journal-title":"Hepatology"},{"issue":"67","key":"1826_CR30","first-page":"370","volume":"2017","author":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL. Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;2017(67):370\u201398.","journal-title":"J Hepatol"},{"key":"1826_CR31","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/hepr.13504","volume":"50","author":"Drafting Committee for Hepatitis Management","year":"2020","unstructured":"Drafting Committee for Hepatitis Management. Japan Society of Hepatology Guidelines for the management of hepatitis B virus infection: 2019 update. Hepatol Res. 2020;50:892\u2013923.","journal-title":"Hepatol Res"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-021-01826-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-021-01826-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-021-01826-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T22:13:51Z","timestamp":1673388831000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-021-01826-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1826"],"URL":"https:\/\/doi.org\/10.1007\/s00535-021-01826-8","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"type":"print","value":"0944-1174"},{"type":"electronic","value":"1435-5922"}],"subject":[],"published":{"date-parts":[[2021,10,1]]},"assertion":[{"value":"15 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}